TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06410911

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcostal Transversus Abdominis Plane block in patients undergoing open cholecystectomy surgery.
Description: Subcostal Transversus Abdominis Plain block will be performed under ultrasound guidance using a 5-10 MHz linear transducer. The needle will be inserted perpendicular to the skin 2 fingers below the costal~margin, just lateral to the rectus abdominis muscle. After confirming the needle tip's location within the TAP, 20 mL of 0.25% bupivacaine will be injected on both sides in patients undergoing open cholicystectomy surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Block in patients undergoing open cholecystectomy
Description: Ultrasound-guided Erector Spinae block using 20 mL of 0.25% bupivacaine will be injected bilaterally at the T7- T8 vertebral level in patients undergoing open cholecystectomy The probe will be advanced 3 cm to the right lateral direction and rotated 90 degrees, and the transverse processes will be determined . Next, 5 mL of 2% lidocaine will be administered to the predicted needle entry point. A 22-gauge, peripheral nerve block needle will cephalocaudally advanced by the in-plane technique. The needle tip will be continuously advanced toward the transverse process to 1-2 mm before contact with the transverse process. After negative aspiration, 20 ml of 0.25% bupivacaine will be injected with intermittent negative aspirations into the fascia of the erector spinae muscle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sbcostal transversus Abdominis block and erector spinae block for both groups
Description: Each patients group will recieve a type of block by injecting 20 ml of 0.25% bupivacaine on each side in patients undergoing open cholecystectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sbcostal transversus Abdominis block and erector spinae block for both groups
Description: Each patients group will recieve a type of block by injecting 20 ml of 0.25% bupivacaine on each side in patients undergoing open cholecystectomy
Study: NCT05080621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ripretinib
Description: 50 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ripretinib
Description: 50 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: 15 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: 15 mg tablets
Study: NCT05560516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qutenza
Description: Capsaicine patch: Qutenza 8% patch will be applied to the skin according to the instruction of the manufacturer. After application of local anesthetics on the skin, a Qutenza 8% patch will be placed. 1-4 patches will be placed and can be adjusted to the right size, depending on the surface of the CIPN. The patch(es) will be removed after 30-60 minutes. The effect will last about 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Duloxetine tablets: In week 1 patients will receive 30 mg duloxetine one time per day. In week 2 the dose will be increased to 60 mg one time per day. In case of inacceptable adverse events the patient is allowed to reduce the dose to 30 mg one time per day after consultation with the researcher or physician.
Study: NCT05806099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBS303
Description: Phase I: The patients confirming to the eligibility criteria will be assigned to one of the 7 dose groups (0.05/0.15/0.45 mg \~ 1.5/6/60 mg, respectively) based on the sequence of inclusion. Each patient will receive MBS303 as per the schedule specified in the respective arms. Based on the safety data of the previous dose groups, if pretreatment with MIL62 is required after disussion by the sponsor and the investigators, the subject should be given an IV infusion of MIL62 1000 mg single dose on the D-7.~Phase Ⅱ: One or two recommended doses will be selected based on the results of Phase I. Each patient will receive one of the two recommended doses MBS303 as step-up doses on D1 (low dose) and D8 (intermediate dose) of C1 and at the target dose on D1 of C2-17 (21-day cycles). Based on the previous safety data, if pretreatment with MIL62 is required after disussion by the sponsor and the investigators, the subjects should be given an IV infusion of MIL62 1000 mg single dose on the D-7
Study: NCT05763459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-7262
Description: Drug: ABBV-CLS-7262 Drug: Digoxin Drug: Rosuvastatin
Study: NCT05051787

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood and milk samples
Description: 2 types of samples will be taken over the same time slots in breastfeeding mothers treated with amoxicillin for at least 2 days:~* 3 breast milk collections of about 20 ml each made using an electric breast pump provided to the participant.~* 3 blood samples of approximately 5 ml each.
Study: NCT06150079

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pes-Guided PEEP titration
Description: Lung recruitment is performed at each time point, involving a switch from volume-controlled (VCV) mode to pressure-controlled (PCV) mode with a pressure setting of 20 cmH2O, RR of 15 bpm, I:E ratio of 1:1, FiO2 of 0.4, and PEEP of 5 cmH2O. During lung recruitment, PEEP is gradually increased in increments of 5 cmH2O, maintained for 5 respiratory cycles until PEEP reaches 20 cmH2O and airway pressure reaches 40 cmH2O, and then maintained for 10 respiratory cycles. After lung recruitment, ventilation is adjusted based on the target PEEP. Each PEEP titration should ensure adequate muscle relaxation, volume status, and hemodynamic stability. PEEP is chosen to maintain a positive transpulmonary pressure at end-expiration (Ptp_ee = PEEP - Pes_ee). Each PEEP titration should ensure adequate muscle relaxation, volume status, and hemodynamic stability.
Study: NCT06433466

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videos featuring influencers promoting e-cigarettes alongside healthy lifestyle activities
Description: Young adults were randomly shown 10 videos, featuring influencers promoting e-cigarettes alongside healthy lifestyle activities (experimental group), or a healthy lifestyle activity alone (control).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Videos featuring influencers promoting e-cigarettes alongside healthy lifestyle activities
Description: Young adults were randomly shown 10 videos, featuring influencers promoting e-cigarettes alongside healthy lifestyle activities (experimental group), or a healthy lifestyle activity alone (control).
Study: NCT06162819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: Amitriptyline will be used for prophylaxis of migraine, also used as antidepressant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flunarizine 5mg
Description: Flunarizine will be used for prophylaxis of migraine,
Study: NCT06198517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moxibustion
Description: The experimental group received moxibustion of Zhongji, Guanyuan, and Qihai for 30 min qd starting on the first day after HSCT was performed until the 14th day after transplantation, while treated conventionally.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Symptomatic treatment
Description: The control group received conventional symptomatic treatment.
Study: NCT05015595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine Oral Tablet
Description: Thirty-two-week double-blind up-titration treatment period (from T0 to T4): patients will be randomly assigned to one of two arms (Memantine or placebo) in a 1:1 ratio and will receive a daily administration of Memantine/placebo up to 20mg/day. Eight-week double-blind down-titration treatment period (from T4 to T5): At T4, the dose of Memantine/placebo will be reduced at 10mg/day due to safety reasons before the end of treatment (T5).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Thirty-two-week double-blind up-titration treatment period (from T0 to T4): patients will be randomly assigned to one of two arms (Memantine or placebo) in a 1:1 ratio and will receive a daily administration of Memantine/placebo up to 20mg/day. Eight-week double-blind down-titration treatment period (from T4 to T5): At T4, the dose of Memantine/placebo will be reduced at 10mg/day due to safety reasons before the end of treatment (T5).
Study: NCT04874961

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tensiofytol®
Description: standardized olive extract

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: contains excipients only
Study: NCT05253534

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlaucoT Glaucoma Treatment Device
Description: In this study, flicker light therapy, the effectiveness of which was investigated in the treatment of glaucoma based on some methods used in different diseases, is described for the first time in glaucoma.~Studies investigating the neurodegenerative properties of glaucoma have found similarities in the pathophysiology of Alzheimer's disease and glaucoma.~40 Hz flicker of light Alzheimer 's the positive effects on the knitted cortex have also been shown in studies. 40 Hz flicker light is aimed to reduce glaucoma and retinal ganglion cell loss due to glaucoma, by reducing neurodegeneration by decreasing amyloid and metabolite accumulation by increasing both microglial phagocytic activation effect and retinal blood flow.
Study: NCT05553951

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Controlgroup
Description: The control group and intervention group will receive daily text message reminders twice a week to take their medications and to rinse their nose.
Study: NCT05976594

Intervention type: DIAGNOSTIC_TEST
Intervention: serology and virology detection of hepatitis E virus
Description: Serum will be tested for HEV serology and virology, including HEV-IgM, HEV-IgG, HEV-antigen, and HEV-RNA for HEV species A (HEV-A) and HEV species C (HEV-C)，and further HEV genotyping for those positive for HEV-RNA.

Intervention type: DIAGNOSTIC_TEST
Intervention: serology and virology detection of hepatitis E virus
Description: Serum will be tested for HEV serology and virology, including HEV-IgM, HEV-IgG, HEV-antigen, and HEV-RNA for HEV species A (HEV-A) and HEV species C (HEV-C)，and further HEV genotyping for those positive for HEV-RNA.
Study: NCT05094154

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti-pseudomonal cephalosporin
Description: Providers will be prompted to order an anti-pseudomonal cephalosporin, such as cefepime with a dose range of 500 mg, 1,000 mg, or 2,000 mg, and frequency every 6, 8, 12, or 24 hours based on provider discretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti-pseudomonal penicillin
Description: Providers will be prompted to order anti-pseudomonal penicillin, such as piperacillin-tazobactam with a dose range of 3.375 g or 4.5 g and frequency every 6, 8, or 12 hours based on provider discretion.
Study: NCT04429425

Intervention type: PROCEDURE
Group type: OTHER
Intervention: epidural anesthesia
Description: epidural anesthesia through epidural injection of a local anaesthetic combined with an opioid
Study: NCT06069557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory exercise
Description: This group will undergo intervention. The participants will be assessed in terms of abdominal distension and shoulder pain in preoperative period. Respiratory exercise training will be given in the preoperative period. At the 1st, 2nd, 3rd, 4th, 5th, 4th, 5th, and 6th hours postoperatively, 10 deep breathing exercises will be performed in semi fowlers 45º position. During this 6-hour period, the patient will be asked to give 10 deep breaths into the incentive spirometer every 2 hours. Patients will be evaluated for abdominal distension and shoulder pain at the 1st, 2nd, 3rd, 4th, 5th, and 6th hours postoperatively and mobilization times will be measured in the first 6 hours.
Study: NCT05553951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Patients in the intervention group will receive systematic and structured nursing guidance regarding their adherence, which includes proper use of nasal irrigation once or twice daily, nasal steroid/drops, use of inhaled medications, follow-up of smoking status. The intervention group will receive guidance videos which have been prepared prior to the study and will be standard for the intervention group. Guidance videos will cover the correct use of nasal irrigation, inhalation steroid, and nasal steroid/drops.
Study: NCT06474741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: in-app notification
Description: Parents will receive bi-weekly prompts in a baby monitor app to change infant's orientation within crib, allow for tummy time several times per day, alternate the side from which infants are fed, alternate the side the infant faces during carrying, and in general note any side preferences of the infant so that positioning can assist in symmetry.
Study: NCT05392192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-629
Description: Subjects will be randomized to receive both ADX-629 and placebo in one of two treatment sequences: One group of subjects will receive ADX-629 during the 1st treatment period and matching placebo during the 2nd Treatment while subjects the other sequence/group will receive the matching placebo in the 1st treatment period and ADX-629 in the 2nd treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized to receive both ADX-629 and placebo in one of two treatment sequences: One group of subjects will receive ADX-629 during the 1st treatment period and matching placebo during the 2nd Treatment while subjects the other sequence/group will receive the matching placebo in the 1st treatment period and ADX-629 in the 2nd treatment period.
Study: NCT04975607

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: The three live music therapy sessions will be provided after lung transplant. All three music therapy sessions will employ a variety of data-based interventions to address pain, anxiety, and improve relaxation. Music therapy interventions may include patient preferred live music, active music listening, singing or other active music-making, and guided breathing and relaxation.
Study: NCT06534671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diltiazem
Description: IV diltiazem (0.25 mg/kg) will be given over 2 minutes, with ECG and blood pressure measurements at baseline, 2, 5, 7, 10, 15 and 20 minutes. If at 10 minutes there is no QT shortening, and blood pressure is stable, an additional dose (0.35 mg/kg) will be given with ECG and blood pressure measurements at 17, 20, 22, 25, 30 and 35 minutes.
Study: NCT06011031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novaloc attachment
Description: Each patient will be restored with 4 implants retained maxillary overdenture with the assigned attachment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Locator attachment
Description: Each patient will be restored with 4 implants retained maxillary overdenture with the assigned attachment
Study: NCT04946448

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIT diet
Description: Dietary intervention as add-on therapy to biologicals
Study: NCT05639920

Intervention type: COMBINATION_PRODUCT
Intervention: Scoreing
Description: Validation of Emergency surgery score in predicting mortality and mortality in Egyptian patients undergoing Emergency laparotomy
Study: NCT04562779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone 380 MG
Description: XR naltrexone to be given once prior to hospital discharge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: IV ketamine infusion to be given once prior to hospital discharge

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced linkage
Description: Includes in-hospital intake at outpatient addiction clinic plus contingency management related to follow-up

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced linkage
Description: Includes in-hospital intake at outpatient addiction clinic plus contingency management related to follow-up

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced linkage
Description: Includes in-hospital intake at outpatient addiction clinic plus contingency management related to follow-up
Study: NCT05868668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused shockwave
Description: Storz Duolith SD-1 (Storz Medical, Tagerwilen, Switzerland)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radial wave
Description: Zimmer enPuls Pro (Zimmer MedizinSysteme GmbH, Neu-Ulm, Germany)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Handheld sham probe
Study: NCT05675982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAR-T cells monitoring
Description: monitoring of circulating DNA by blood sample
Study: NCT04648878

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybrid combination of physical therapy and powered exoskeleton
Description: 18 alternating visits of conventional physical therapy and powered exoskeleton gait training with a wearable robotic powered exoskeleton , three times a week for approximately 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Powered Exoskeleton Only
Description: 18 visits of powered exoskelton only, three times a week for approximately 6 weeks
Study: NCT05399888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB080
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB080
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB080
Description: Administered as specified in the treatment arm.
Study: NCT05999851

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arterial applanation tonometry
Description: Arterial applanation tonometry will be performed at the carotid and femoral level by the PulsePen device (Software WPulsePen version 2.3.1, DiaTecne, Milan, Italy), while the subject is lying in the horizontal position and after 5 minutes of rest.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In vivo endothelial glycocalyx measurement
Description: The in vivo microscopy (GlycoCheck system) is performed in the sublingual capillaries during the morning, with the participant sitting on a chair. The sublingual capillaries are visualized using an SDF video microscope (Capiscope handheld, KK Research technology Ltd).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serum markers of angiogenesis and endothelial dysfunction
Description: ELISA assays to measure serum circulating markers of angiogenesis and endothelial dysfunction (ANG-1, ANG-2, ET-1, ICAM-1 and VCAM-1).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood chemistry test
Description: Immunochemistry analysis of serum levels of uric acid, total cholesterol, LDL-cholesterol, HDL-cholesterol, Triglycerides, Lipoprotein (a)
Study: NCT05399888

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIIB080
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB080-matching placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB080-matching placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIIB080-matching placebo
Description: Administered as specified in the treatment arm.
Study: NCT05469360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIO752
Description: A single intrathecal (cerebrospinal) injection of NIO752 of Dose A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIO752
Description: A single intrathecal (cerebrospinal) injection of NIO752 at dose B

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: A single intrathecal injection of matching placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: A single intrathecal injection of matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIO752
Description: Multiple intrathecal injections of NIO752 of Dose A
Study: NCT05503420

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masticatory muscle training exerciser
Description: In addition to the normal stroke rehabilitation training, the participants will be instructed on an active range of motion (AROM) exercise to improve coordination of the masticatory muscles. This part will be performed with a 5-second hold at the end of the range of motion for each motion, with 10 repetitions performed for each motion. In addition, each participant will be provided with a device, a U-shaped apparatus covered by silicon and having 3 small springs inside to provide resistance during chewing to be placed inside the mouth for carrying out a chewing exercise. The participant will be instructed to perform a chewing exercise using the device for around 10 minutes each time, twice a day, and 7 days per week. The exercise includes isotonic and isometric muscle training.
Study: NCT06133127

Intervention type: OTHER
Group type: OTHER
Intervention: Frailty assessment
Description: Assessments for all patients : isometric quadriceps strength, malnutrition by RFH-NPT and MNA questionnaires, body composition by circumference and triceps skinfold, frailty by LFI and SPPB, muscle cramps by Cramp questionnaire.
Study: NCT05999851

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serum xanthine oxidase activity
Description: Serum xanthine oxidase (XO) activity will be assessed in blood samples measuring the ability of XO to produce uric acid
Study: NCT04008680

Intervention type: OTHER
Group type: OTHER
Intervention: EQ-5D-5L survey internal consistency
Description: To see how increasing the number of questionnaires affects the internal consistency of the EQ-5D-5L.

Intervention type: OTHER
Group type: OTHER
Intervention: EQ-5D-5L survey internal consistency
Description: To see how increasing the number of questionnaires affects the internal consistency of the EQ-5D-5L.

Intervention type: OTHER
Group type: OTHER
Intervention: EQ-5D-5L survey internal consistency
Description: To see how increasing the number of questionnaires affects the internal consistency of the EQ-5D-5L.

Intervention type: OTHER
Group type: OTHER
Intervention: EQ-5D-5L survey internal consistency
Description: To see how increasing the number of questionnaires affects the internal consistency of the EQ-5D-5L.
Study: NCT06173960

Intervention type: DEVICE
Intervention: atherectomy
Description: Jetstream atherectomy in combination with Ranger paclitaxel elution balloon (Drug Coated Balloon (DCB))